SCHEMBL30129623

SCHEMBL30129623

Oc1cccc(-c2cnc3c(n2)OCCO3)c1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 3/20 0.57
HSD17B2 P37059 3/20 0.57
PIK3CG P48736 3/20 0.50
PIK3CA P42336 6/20 0.47
PIK3CB P42338 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
PIK3CD O00329 2/20 0.45
ATR Q13535 2/20 0.43
METAP2 P50579 1/20 0.43
CHEK1 O14757 1/20 0.43
MAP4K4 O95819 1/20 0.42
KDM1A O60341 1/20 0.42
PRKDC P78527 1/20 0.41
FYN P06241 2/20 0.40
CYP19A1 P11511 1/20 0.40
MAPK1 P28482 1/20 0.40
MAPK8 P45983 1/20 0.40
MAPK9 P45984 1/20 0.40
MAPK10 P53779 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30129746 0.76 HSD17B1 (0.47) HSD17B1HSD17B2MAP4K4FYN
SCHEMBL3024116 0.74 BCHE (0.67) HSD17B1HSD17B2ATRMAPK10
SCHEMBL1180306 0.74 HSD17B1 (1.00) HSD17B1HSD17B2PIK3CGPIK3CAPIK3CB
SCHEMBL30129734 0.73 HSD17B1 (0.45) HSD17B1HSD17B2PIK3CAPIK3CDMETAP2
SCHEMBL2317303 0.71 HSD17B1 (0.51) HSD17B1HSD17B2PIK3CGPIK3CAPIK3CB
SCHEMBL10200397 0.70 PIK3CA (0.43) HSD17B1HSD17B2PIK3CAPIK3CDMETAP2
SCHEMBL30186373 0.69 HSD17B1 (0.79) HSD17B1HSD17B2PIK3CGPIK3CAPIK3CB
SCHEMBL2319574 0.69 HSD17B1 (0.51) HSD17B1HSD17B2PIK3CGPIK3CAPIK3CB
SCHEMBL2321967 0.69 HSD17B1 (0.56) HSD17B1HSD17B2PIK3CGPIK3CAPIK3CB
SCHEMBL30862097 0.68 HSD17B1 (0.66) HSD17B1HSD17B2METAP2CHEK1MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20230027684-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-26 US disclosed
US-20230008867-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230008867-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 HSD17B1 2388/4885HSD17B2 2816/4885PIK3CG 2223/4885
US-20230027684-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 HSD17B1 2342/4885HSD17B2 2758/4885PIK3CG 2230/4885
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 HSD17B1 2342/4885HSD17B2 2758/4885PIK3CG 2230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.